Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	11/21/2006 12:51:10 AM
	Read Replies (1) of 10280

Sepracor "outperform," target price raised Monday, November 20, 2006 10:49:50 AM ET Credit Suisse NEW YORK, November 20 (newratings.com) - Analyst M Goodman of Credit Suisse maintains his "outperform" rating on Sepracor Inc (SEPR.NAS). The target price has been raised from $60 to $65. In a research note published this morning, the analyst mentions that the transition for inhalers from CFCs to HFAs is likely to be quicker than was earlier expected on account of a pick up in the phase down of CFC production. This is likely to result in continued acceleration in Xopenex MDI Rxs, with significant growth in 2007 and 2008, the analyst says. Lunesta TRxs have continued to accelerate, since the sleep disorder market and Lunesta's market share are growing, Credit Suisse adds.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next